- Home
- NAN vs ALDX Comparison
NAN vs ALDX Comparison
Compare NAN & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAN
- ALDX
- Stock Information
- Founded
- NAN 1999
- ALDX 2004
- Country
- NAN United States
- ALDX United States
- Employees
- NAN N/A
- ALDX 9
- Industry
- NAN Investment Managers
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- NAN Finance
- ALDX Health Care
- Exchange
- NAN Nasdaq
- ALDX Nasdaq
- Market Cap
- NAN 352.5M
- ALDX 398.3M
- IPO Year
- NAN N/A
- ALDX 2014
- Fundamental
- Price
- NAN $11.39
- ALDX $6.67
- Analyst Decision
- NAN
- ALDX Strong Buy
- Analyst Count
- NAN 0
- ALDX 2
- Target Price
- NAN N/A
- ALDX $10.00
- AVG Volume (30 Days)
- NAN 74.6K
- ALDX 767.7K
- Earning Date
- NAN 01-01-0001
- ALDX 05-01-2025
- Dividend Yield
- NAN 4.37%
- ALDX N/A
- EPS Growth
- NAN N/A
- ALDX N/A
- EPS
- NAN N/A
- ALDX N/A
- Revenue
- NAN N/A
- ALDX N/A
- Revenue This Year
- NAN N/A
- ALDX N/A
- Revenue Next Year
- NAN N/A
- ALDX N/A
- P/E Ratio
- NAN N/A
- ALDX N/A
- Revenue Growth
- NAN N/A
- ALDX N/A
- 52 Week Low
- NAN $9.11
- ALDX $3.10
- 52 Week High
- NAN $11.34
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- NAN 41.14
- ALDX 54.67
- Support Level
- NAN $11.32
- ALDX $6.30
- Resistance Level
- NAN $11.52
- ALDX $6.81
- Average True Range (ATR)
- NAN 0.10
- ALDX 0.44
- MACD
- NAN -0.01
- ALDX -0.05
- Stochastic Oscillator
- NAN 51.22
- ALDX 49.52
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.